Strong Year-Over-Year Revenue Growth
The company generated net revenue of $86.7 million for the full-year 2024, representing growth of 33% year-over-year, driven by strong sales of self-tissue products and bone fusion products.
Positive Adjusted EBITDA
The company achieved positive adjusted EBITDA of $2.7 million in 2024, an increase of $2.6 million compared to 2023, reflecting significant profitability improvements within the Sanara Surgical segment.
Commercial Expansion and Strategic Agreements
Sanara expanded its sales coverage, increased distributor partners to over 350, and entered into strategic agreements with Biomimetic Innovations, securing exclusive rights to innovative products.
Successful Financial Management
Net cash use in operating activities was essentially break-even in 2024, with only $24,000 of cash used, compared to $3.2 million in 2023, and a new debt facility was secured for up to $55 million.
Fourth Quarter Revenue Performance
Fourth quarter net revenue grew 49% year-over-year to $26.3 million, with soft tissue repair products increasing 56% and bone fusion products increasing 8%.
Innovation and Intellectual Property Development
The company submitted 11 provisional patent applications in 2024, covering innovations in antimicrobial technologies and hydrolyzed collagen.